Abstract: The present disclosure relates to a modified antibody, or antigen-binding fragment thereof, specific for nectin cell adhesion molecule 4 (nectin-4). The present disclosure also relates to a method of detecting or diagnosing whether a subject has, or is at risk of developing a tumor, or assessing a prognosis of a tumor and a pharmaceutical composition for use in treating, prophylactic treating and/or preventing tumor in a subject afflicted with the tumor.

Abstract: The present disclosure relates to a modified antibody, or antigen-binding fragment thereof, specific for nectin cell adhesion molecule 4 (nectin-4). The present disclosure also relates to a method of detecting or diagnosing whether a subject has, or is at risk of developing a tumor, or assessing a prognosis of a tumor and a pharmaceutical composition for use in treating, prophylactic treating and/or preventing tumor in a subject afflicted with the tumor.

Abstract: The present invention relates to epitopes located in CAIX and anti-CAIX antibodies having binding activity with cancer cells. The present invention also relates to the composition and application of the CAIX epitopes and anti-CAIX antibodies in the diagnosis, prevention and/or treatment of cancers.

Abstract: The present disclosure relates to a method for obtaining an antibody or antigen-binding fragment thereof that specifically binds to and against a tumor sample, comprising: administering autologous dendritic cells to a subject; taking immune cells and a tumor sample from the subject; constructing an antibody library of the immune cells; and screening the antibody library to obtain the antibody or a fragment thereof specifically binding to and against the tumor sample. The disclosure also relates to a method for engineering immune cells, an antibody or antigen-binding fragment thereof that specifically binds to and against a tumor sample and uses thereof.

Abstract: A close-system cell isolation device includes a first culture bag, a second culture bag, immunomagnetic beads, and a connecting tube. The first culture bag and the second culture bag are closely connected with each other through the connecting tube. The first culture bag has the immunomagnetic beads and cells. When the first culture bag is forced by a magnetic force and an external force, the cells uncaptured by the immunomagnetic beads are moved from the first culture bag to the second culture bag through the connecting tube by the external force, and the cells captured by the immunomagnetic beads are retained in the first culture bag by the magnetic force. Accordingly, the cell isolation can be performed without contamination.

Abstract: The invention relates to antibodies against ?-enolase I, their pharmaceutical compositions and diagnosis and treatment uses. Particularly, the invention provides polyclonal anti-?-enolase I antibodies and monoclonal single-chain variable fragment (scFv) anti-?-enolase antibodies, pharmaceutical compositions containing the same and their uses in uses in diagnosis and treatment of cancers, autoimmune disorders, ischemia and bacterial infection.

Abstract: The invention relates to antibodies against ?-enolase I, their pharmaceutical compositions and diagnosis and treatment uses. Particularly, the invention provides polyclonal anti-?-enolase I antibodies and monoclonal single-chain variable fragment (scFv) anti-?-enolase antibodies, pharmaceutical compositions containing the same and their uses in uses in diagnosis and treatment of cancers, autoimmune disorders, ischemia and bacterial infection.